Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04853043 · ClinicalTrials.gov registry record · Phase 2
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04853043: Clinical Trial Phase 2 study, sponsored by University of Utah.
NCT04853043 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04853043, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the epidermal growth factor receptor (EGFR) inhibitor, Cetuximab in patients with metastatic colorectal cancer (mCRC) harboring Adenomatous polyposis coli (APC), tumor protein p53 (TP53) and RAS mutations.
Primary Outcome
Evaluate the PFS among patients treated with cetuximab in APC, TP53 and RAS mutated refractory metastatic colorectal cancer. PFS will be measured from the date of first dose of study drug until the first documented radiographic evidence of disease progression by Response Evaluation Criteria In Solid Tumors Criteria (RECIST) criteria 1.1, clinical progression per investigator judgement, start of new anti-cancer therapy, or death from any cause. Per RECIST 1.1 for target lesions, Progressive Dis
Interventions
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2024-05-03 |
| Phase | Phase 2 |
Why NCT04853043 stopped before completion
NCT04853043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT04853043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04853043 about?
NCT04853043 is a clinical study titled "Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer". A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the epidermal growth factor receptor (EGFR) inhibitor, Cetuximab in patients with metastatic colorectal cancer (mCRC) harboring Adenomatous polyposis coli (APC), tumor protein p53 (TP53) and RAS mutations.
What is the current status of trial NCT04853043?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-11-03. Estimated completion is 2024-05-03.
What interventions are being tested in trial NCT04853043?
The interventions under investigation include: Cetuximab (DRUG).
Who is sponsoring clinical trial NCT04853043?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04853043's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI